Halberd Corp. Files Provisional Patent Application Complementing Patented Extracorporeal Radio Frequency/Laser Projects
Jackson Center, Pennsylvania--(Newsfile Corp. - June 1, 2021) - Halberd Corp. (OTC Pink: HALB) announced the filing of a U. S. joint provisional patent application titled, "Antibody Conjugated Nanoparticle Assay And Treatment For SARS-CoV-2." The innovation is a result of Halberd's Sponsored Research conducted at Arizona State University (ASU). The provisional patent application covers technology developed to facilitate conjugation of metallic nanoparticles with antibodies against various bacteria and SARS-CoV-2, for elimination via radio waves. Additionally, the patent discloses the use of such a conjugated moiety as a means of detecting the presence and level of the SARS-CoV-2 viral load in a patient.
Dr. Mitchell S. Felder, Halberd Corporation's Chief Technical Officer and co-inventor of the technology, stated, "The conjugation of a metallic nanoparticle with either a bacterial or viral antibody which produces a stable moiety is not an obvious procedure. The researchers at ASU did a phenomenal job in a short period of time, allowing our extracorporeal disease eradication testing to go forward as planned. A side benefit of this work is that the moiety is potentially capable of detecting not only the presence of SARS-CoV-2, or a bacterial infection - but also of detecting the level of disease load in the patient."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "Although our research was prompted by and focused on COVID-19, the technology developed has demonstrated far reaching benefit towards the detection and elimination of other viruses and bacterial infections. Through Halberd's patented extracorporeal process of exposing the infected blood or cerebral spinal fluid to tuned radio waves or laser emissive energy, we believe we will be able to successfully treat a wide range of illnesses and diseases."
About Halberd Corporation.
Halberd Corporation (OTC Pink: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies:
|Title||Patent/ Application No.||Filing Date||Status/Document|
|*Method for Treating and Curing COVID-19 Infection||US 62/989981||03/16/2020||Provisional|
|*Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients||US 63/007207||04/08/2020||Provisional|
|COVID-19 Inflammatory Cytokine Storm Treatment||PCT/US21/26386||04/08/2021||International PCT|
|*Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus||US 63/013104||04/21/2020||Provisional|
|Treating and Curing COVID-19 Infection Utilizing a Laser||PCT/US21/28368||04/21/2021||International PCT|
|*Method For The Rapid Identification Of COVID-19 Infection||US 63/049441||07/08/2020||Provisional|
|*Nasal Spray To Prevent The Transmission Of COVID-19 Between Humans||US 63/080735||09/20/2020||Provisional|
|*Nasal Spray To Prevent The Transmission Of The COVID-19 Virus||US 63/108301||10/31/202||Provisional|
|*Method For Treating And Curing COVID-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus||US 63/111043||11/08/2020||Provisional|
|*Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (COVID-19 Virus)||US 63/135695||01/10/2021||Provisional|
Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/85811